The role of modified forms of calcium in the preparations for antirezorbtivei pathogenetic therapy in patients with osteoporosis, hypo- or normocalcemia

• Alexander S. Ametov
• Elena V. Doskina
• N.V. Kapustina

Abstract

Osteoporosis is a progressive systemic disease of the skeleton characterized by reduced bone mass and impaired bone micro-leading to increased bone fragility and risk of fracture. The level of calcium intake in patients with OP and those with osteopenia are much lower than in the healthy population. Thus, a pressing question remains about the possibility of compensation of calcium deficiency in different situations. To solve this problem, a study was conducted - we studied the efficacy, tolerability and safety of Micellar Asset in preparation for carrying out antirezorbtivei therapy in patients with Hypo - or normocalcemia and osteoporosis. The study involved 30 patients with osteoporosis, Hypo - or normocalcemia that meet the criteria of inclusion/exclusion. After screening by the method of random numbers, patients were divided into 2 groups, 20 patients received Micellar-Asset and 10 patients received a placebo.

During clinical trials on the use of Micellar Asset in preparation for antiresorptive therapy in patients with Hypo - or normocalcemia and osteoporosis there were no cases of adverse events, individual intolerance, side effects. In patients with hypocalcemia (30% of the total number of patients in the main group) on a background of a 3-month application Micellat Asset was marked normalization of a level of calcium in the blood based on the indicators of markers of bone metabolism (including β-CrossLaps P1NP, ionized CA in the blood, Sa daily in the urine). In patients with normocalcemia on the background of the 3-month application Micellat Asset in the standard dosage is not marked hypercalcemia in any of the patients. For a 3-month observation period showed no statistically significant changes in ECG study was not marked by the appearance of new complaints are of cardiac nature, evidence of the cardiac safety of Micellar Asset. Over the whole observation period showed no statistically significant changes in renal ultrasound, is not marked the emergence of any new complaints of urogenital character, and also showed no statistically significant changes in the overall analysis of urine of patients, indicating the safety of Micellar Asset. All patients treated with Micellar-an Asset, awarded the best portability Alendronova acid is less pronounced arthralgia, flu-like symptoms and myalgia.

Keywords:osteoporosis, calcium, treatment of osteoporosis, antiresorptive therapy, hypocalcemia

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)